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Despite intensive study of p53, the regulation of p53
cellular localization is still poorly understood. This is an
overview of the elements and molecules involved in p53
nucleocytoplasmic transportation. These include the nuclear
import and export signals of p53, inhibition of p53 nuclear
import and export by oligomerization, MDM2-mediated p53
nuclear export, and possible roles of p53 phosphorylation in
regulating p53 cellular localization. Finally, questions
regarding p53 cellular trafficking will also be discussed.
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The p53 tumor suppressor is one of the most important
molecules in regulating cell growth and protecting cells
from malignant transformation. The importance of p53 is
reflected by the fact that over 50% of all human cancers
have p53 gene mutations [1,2]. Besides structural mutation,
the functional inactivation of wild-type p53, such as the
disruption of pathways involved in regulating p53 function,
can also contribute to malignancy. A thorough under-
standing of the mechanism controlling p53 function will not
only increase our knowledge of cancer biology but also
may lead to the development of new cancer therapies
targeting aberrant p53 pathways.
In a normal cell, the p53 protein is kept at a low con-
centration by rapid degradation. In addition, p53 probably
exists in a latent, inactive form [3,4]. Several stressful
situations, including genotoxic DNA damage, hypoxia,
deprivation of growth factors, and loss of cell anchorage or
cell±cell contact, can induce the formation of functional
p53 [5]. Activation of p53 can be modulated at three levels:
(a) an increase of the p53 protein concentration either by
enhanced translation or elongated half-life; (b) the trans-
formation of the p53 protein from a latent to an active
conformation; and (c) the translocation of the p53 protein
from the cytoplasm to the nucleus. While a number of
studies have been performed to elucidate the modulation of
p53 activity at the first two levels, few have addressed the
regulation of p53 cellular localization. In this paper, we
review what is known about p53 cellular localization and
discuss the remaining issues regarding regulation of p53
nucleocytoplasmic transportation.
T H E p 5 3 N U C L E A R I M P O R T I S T I G H T LY
R E G U L A T E D A N D E S S E N T I A L F O R I T S
N O R M A L F U N C T I O N
It was demonstrated in the early 1980s that p53 is cyto-
plasmic in most normal cells [6,7]. In transformed cells or
rapidly growing normal cells, however, p53 is primarily
located in the nucleus [6,7]. It was later reported that the
nucleocytoplasmic translocation of p53 is tightly regulated
during the cell cycle in normal fibroblasts [8]. In these
cells, p53 accumulates in the cytoplasm during the G1
phase and enters the nucleus during the G1 /S phase
transition. A short period after the beginning of S phase,
p53 cycles back to the cytoplasm. These data imply that
p53 activity can be spatially regulated during the cell
cycle. Indeed, it has been demonstrated that p53 is subject
to both nuclear import and export via a fast, energy-
dependent pathway [9].
Working principally as a transcription factor, the p53
nuclear import or retention is essential for its normal
function in growth inhibition [10,11] or induction of apop-
tosis [12]. Thus, cellular mechanisms must exist to regulate
the dynamic nucleocytoplasmic transportation of p53 either
through enhanced nuclear import or decreased nuclear
export. Studies have shown that wild-type p53 is abnor-
mally sequestered in the cytoplasm in a subset of human
tumor cells such as breast cancers, colon cancers, and
neuroblastoma [13±15]. Although it is not clear whether
this phenotype is directly linked to the malignancy, it
suggests that tumorigenesis could result from a defect in the
regulation of p53 nuclear import.
N U C L E A R I M P O R T A N D E X P O R T
S I G N A L S O F p 5 3
The nuclear localization signal (NLS) and nuclear export
signal (NES) are the essential elements for a protein
subjected to nucleocytoplasmic transportation. The typical
NLS is either monopartite or bipartite (Table 1). The
monopartite NLS consists of a single, short stretch of
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several basic amino acids. The bipartite NLS contains
two separated clusters of basic residues. Nuclear import
is initialized by binding of the NLS to the importin a
and b complex that mediates the docking of proteins at
the nuclear pore complex [16±18]. On the other hand,
the best understood NES is characterized by a leucine-
rich sequence (Table 1) to which the exportin 1 or CRM1
can bind and direct the protein nuclear export [19±21].
Three monopartite NLSs were originally identified in the
C terminus of p53 based on sequence and mutagenesis
analyses [22]; NLSI [PQPKKKP(316±322)] is the most
active of the three in directing p53 nuclear import. The
other two NLSs, II and III, are much weaker. NLSI was
shown to be able to direct the nuclear import of a cyto-
plasmic protein, pyruvate kinase [23]. However, it was
recently found that NLSI alone is not functional for p53
nuclear import [24]. A basic motif containing Lys305±
Arg306 and a spacer between this motif and the NLSI are
necessary for the entrance of p53 into the cell nucleus
[25,26]. In addition, a complete sequence from Lys305 to
NLSI has stronger binding to importin a than that of NLSI
alone [24]. Thus, the functional NLS of p53 is bipartite
rather than monopartite.
A highly conserved leucine-rich NES has been identified
in the tetramerization domain of p53 (Fig. 1). This intrinsic
NES is both necessary and sufficient to direct p53 nuclear
export [27]. Similar to other proteins containing a leucine-
rich NES, p53 nuclear export is mediated by exportin 1 and
could be inhibited by leptomycin B, a drug known to bind
to exportin 1 [28].
R E G U L A T I O N O F p 5 3
N U C L E O C Y T O P L A S M I C
T R A N S L O C A T I O N B Y
O L I G O M E R I Z A T I O N
The p53 NLS is adjacent to, and the NES is contained
within, the oligomerization domain (Fig. 1). It is thus
possible that oligomerization of p53 may regulate p53
nucleocytoplasmic transport by affecting the accessibility
of the NLS and/or the NES to their respective receptors. It
has been demonstrated that the cytoplasmic localization of
p53 in neuroblastoma cells is the result of enhanced nuclear
export [27]. Ectopic expression of a tetramerization domain,
however, was able to restore the nuclear retention of p53,
suggesting that tetramerization can inhibit p53 nuclear
export, presumably by masking the NES.
We have identified a cytoplasmic sequestration domain
(CSD) that can reduce the efficiency of p53 nuclear import
by blocking the importin a binding [24,25]. This CSD
contains the p53 oligomerization domain and hence
implies that p53 tetramerization may be also involved in
the regulation of p53 nuclear import. Although p53 was
able to enter the nucleus in an oligomerized form [24], it
was observed that mutation of residues that can disrupt
p53 tetramerization but not nuclear export could increase
the efficiency of p53 nuclear import (S.-H. Liang and M.
F. Clarke, unpublished data), indicating that the p53
monomer can enter the nucleus more efficiently than the
oligomer.
It seems that oligomerization of p53 can block both NLS
and NES binding to their receptors. It is thus possible that
p53 oligomerization itself is regulated, switching p53 from
a tetramer to a monomer at the time that p53 needs to
transport in or out of the nucleus.
M D M 2 A N D p 5 3 C E L L U L A R
L O C A L I Z A T I O N
The MDM2 protein is an important regulator of p53
function. MDM2 binds to the transcriptional activation
domain in the N-terminus of p53 [29]. It can also promote
the degradation of p53 by the ubiquitin±proteasome system
[30,31]. MDM2 has been linked to the regulation of p53
nucleocytoplasmic translocation in two ways. First, it was
demonstrated that MDM2 interacts with p53 in the nucleus
and shuttles p53 from the nucleus to the cytoplasm where it
mediates the degradation of p53 [32,33]. Alternatively,
MDM2 could mediate ubiquitination of p53 in the nucleus,
which turns on p53 nuclear export by unmasking the NES
of p53 (C. Maki, Harvard School of Public Health, Boston,
MA, USA, personal communication).
Table 1. Signals for protein nuclear import and export. Bold type
indicates residues shown to be required for signal function.
Signal Sequence Reference
Monoparite NLSs
SV40 T antigen PKKKRKV [56]
Yeast histone H2B GKKRSKV [57]
Human c-myc PAAKRVKLD [58]
Bipartite NLSs
Nucleoplasmin KRPAATKKAGQAKKKKL [59]
Human IL-5 KKYIDGQKKKCGEERRRVNQ [60]
Human RB KRSAEGSNPPKPLKKLR [61]
Human p53 KRALPNNTSSSPQPKKKP [24]
Leucine-rich NESs
HIV-1 Rev LPPLERLTLD [62]
Rat PK1 LALKLAGLDI [63]
Human p53 MFRELNEALELK [27]
Fig. 1. Amino-acid sequences of the C-terminus of p53 protein. The nuclear localization signal (NLS) is from residues 305±322. The nuclear
export signal (NES) is from residues 340±351. The tetramerization domain, as marked in a box, is from residues 326±355.
2780 S.-H. Liang and M. F. Clarke (Eur. J. Biochem. 268) q FEBS 2001
The involvement of MDM2 in regulating p53 cellular
localization is further demonstrated by the observation that
the MDM2 function is directly linked to the nuclear
exclusion of p53 in a subset of tumors such as neuro-
blastomas and breast carcinomas [34]. Inhibition of MDM2
expression by an antisense oligonucleotide, or inhibition of
MDM2 function by P19 (ARF) tumor suppressor protein
result in a relocation of wild-type p53 from the cytoplasm
to the nucleus. On the other hand, it has been reported that
p53 nuclear export is independent of MDM2 binding, based
on the observation that mutant p53 that cannot interact with
MDM2 still undergoes nucleocytoplasmic translocation
[27]. It appears that MDM2 could, in some circumstances,
control p53 nucleocytoplasmic translocation by distinct
mechanisms that may depend on the cell context.
I N V O LV E M E N T O F
P H O S P H O R Y L A T I O N I N T H E
R E G U L A T I O N O F p 5 3 C E L L U L A R
L O C A L I Z A T I O N
Protein phosphorylation has been shown to affect nuclear
import or export of several proteins such as the SV40 large
T antigen [35,36], cyclin B1 [37], nucleolin [38], and
MAPKAP kinase 2 [39]. p53 is known to be phosphorylated
at multiple sites located in both the N- and C-terminal
regions [5,40]. It has been reported that insulin-like growth
factor I could induce an elevated level of phosphorylation
of p53 and a translocation of p53 from the nucleus to the
cytoplasm in MCF-7 human breast cancer cells [41].
Although it is not clear whether this elevated p53 phos-
phorylation is directly involved in the p53 nucleocytoplas-
mic translocation, it is possible that phosphorylation may
affect p53 localization.
There are several specific phosphorylation events which
may be related to the regulation of p53 cellular localization.
As MDM2 is associated with p53 cellular trafficking,
phosphorylation(s) that could inhibit MDM2 binding to p53
may be involved in regulating p53 localization probably by
enhancing the nuclear accumulation of p53. These include
phosphorylation at Ser15 by ataxia telangiectasia mutated
kinase and dsDNA-activated protein kinase [42±44], Thr18
by casein 1-like kinase [45], Ser20 [46,47], and Ser37 by
A±T related kinase and dsDNA-activated protein kinase
[44,48].
Phosphorylation of Ser392 was able to stabilize p53
tetramer formation, and Ser315 phosphorylation largely
reversed the effect of Ser392 phosphorylation [49]. Because
oligomerization may affect p53 nucleocytoplasmic trans-
portation, phosphorylation of Ser315 and Ser392 could thus
work together to regulate p53 cellular localization. In some
cellular compartments, phosphorylation of p53 at Ser392
may reduce the efficiency of p53 nuclear import or export
by enhancing oligomerization of p53.
Phosphorylation that can directly or indirectly influence
the accessibility of NLS or NES to their receptors may also
involved in the regulation of p53 cellular localization. One
potential target is Ser315, a residue located within the
bipartite NLS (residues 305±322) of p53, by cdc2/cyclinB
and cdk2/cyclinA [50,51]; phosphorylation of Ser315 may
therefore may affect p53 nuclear import. Studies are under-
way to test the relationship between these phosphorylations
and p53 cellular localization.
S O M E O T H E R M O L E C U L E S
A S S O C I A T E D W I T H p 5 3 C E L L U L A R
L O C A L I Z A T I O N
Several studies have shown that other proteins may also be
involved in the regulation of p53 cellular localization.
Using a protein synthesis inhibitor, it was demonstrated that
protein synthesis is required to anchor a temperature-
sensitive p53 mutant for nuclear transport [52]. It was
suggested that there are short-lived proteins that can tether
p53 in the cytoplasm. Supporting this theory, it has been
shown that a hsp70 family member, Mot2, could interact
with p53 and inhibit its nuclear import [53]. Transfection
of NIH3T3 cells with mot-2 resulted in an abrogation of
Fig. 2. Postulated pathways of p53
nucleocytoplasmic transportation. (A) By
binding to MDM2 in the nucleus, p53 and MDM2
are together translocated to the cytoplasm,
mediated by binding of CRM1 to MDM2. (B)
MDM2 mediates p53 ubiquitination in the nucleus
which unmasks the NES of p53 for CRM1 binding
and nuclear export. (C) p53 tetramerization, which
may be enhanced by phosphorylation at Ser392,
reduces nuclear export by masking the NES. p53
can resume the monomer form (by mechanisms
that are unclear), which is able to interact with
CRM1 and nuclear export. (D) A cytoplasmic
`tether' that binds to p53 can inhibit p53 nuclear
import probably by blocking the NLS binding to
importin a. (E) Phosphorylation of p53 at Ser315,
for example, may also blocking the NLS
accessibility to importin a. (F) Tetramerization
may mask the p53 NLS and reduce the efficiency
of p53 nuclear import.
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nuclear translocation of wild-type p53 and the repression of
p53-mediated transactivation.
The cell death inhibitor, Bcl2, has been implicated in
p53 nucleocytoplasmic translocation. In murine erythro-
leukemia cells, coexpression of bcl-2 and c-myc can totally
inhibit p53 function by cytoplasmic sequestration [12].
Overexpression of bcl-2 in LNCaP human prostate
carcinoma cells suppressed cell death following DNA
damage and inhibited p53 nuclear import [54]. It appears
that, depending on the cell type, the Bcl2 alone or working
together with other factors can modulate p53 cellular
localization.
In addition to Bcl2, it was reported that the calcium-
dependent protein kinase C could cooperate with a calcium
binding protein, S100B, in regulating p53 nuclear accumu-
lation [55]. It was suggested that cPKC activation by
calcium signalling, together with the expression of S100B,
could result in p53 nuclear translocation in early G1 phase
to initialize a p53-dependent G1 checkpoint control.
C O N C L U S I O N S
It appears that p53 cellular localization can be modulated
by a variety of ways (Fig. 2). It's our belief that more and
more molecules or elements will be identified as being
involved in this process. Remaining questions include the
following. Do these molecules work alone or interact with
each other to function? What signals trigger distinct
mechanisms in controlling p53 cellular localization? How
do cells integrate these varied mechanisms and find a
efficient way to regulate p53 localization? Understanding
all these issues will provide a new insight into the
sophisticated pathways of the regulation of p53 function.
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